MAC-Endo clinical trial

A pilot randomised controlled trial of the efficacy of RRx-001 macrophage-targeted immunotherapy in the management of endometriosis-associated pain

Why?

We therefore aim to examine the safety/tolerability of RRx-001 immunotherapy in patients with endometriosis. In addition, we will generate data that will inform the design of a future larger definitive trial to determine the efficacy of RRx-001 in the management of endometriosis-associated pain.

Who?

•    Pre-menopausal women and those assigned female at birth
•    Aged 18 years and over
•    Chronic pelvic pain of > six months duration from date of consent as per patient reported history
•    Endometriosis identified at laparoscopy or imaging within the last five years from date of consent
•    Use of effective barrier contraception for the duration of their participation (if required)*

Where?

NHS Lothian 

When?

Recruitment is planned to start in the summer of 2025.

Recruitment target

36 participants 

More information

For further details, please contact Priscilla.Fernandez@ed.ac.uk. Please type “MAC-Endo patient enquiry” in the email title section. This will help the team reply to your query sooner.
 

This article was published on